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Abstract
Merck's MK-0518, known as raltegravir, has recently become the first FDA-approved HIV-1
integrase (IN) inhibitor and has since risen to blockbuster drug status. Much research has in turn
been conducted over the last few years aimed at recreating but optimizing the compound's
interactions with the protein. Resulting me-too drugs have shown favorable pharmacokinetic
properties and appear drug-like but, as expected, most have a highly similar interaction with IN to
that of raltegravir. We propose that, based upon conclusions drawn from our docking studies
illustrated herein, most of these me-too MK-0518 analogues may experience a low success rate
against raltegravir-resistant HIV strains. As HIV has a very high mutational competence, the
development of drugs with new mechanisms of inhibitory action and/or new active substituents
may be a more successful route to take in the development of second- and third-generation IN
inhibitors.
Overview
Though many potent inhibitors of the viral life cycle have
arisen over recent years, HIV persists as a global pandemic
with eradication unlikely in the near future. Over 33 mil-
lion people, including 2.5 million children, are living
with HIV worldwide as of December, 2007 [1]. Almost
7000 people are newly infected with HIV, and around
6000 die from AIDS, each day. Due to the lack of educa-
tion about risky behaviors and the lack of access to treat-
ment, low- and middle-income countries remain the
largest producers of new HIV infections, with AIDS being
the leading cause of death in Sub-Saharan Africa. Five per-
cent of all adults are living with HIV or AIDS in this region
[1,2]. Worldwide spending on HIV/AIDS research, treat-
ment, and prevention has risen from $300 million in
1996 to an estimated $10 billion in 2007, but the global
need is projected to be much higher [2,3]. Although novel
estimation procedures have contributed to a more accu-
rate, reduced 2008 global estimate of those living with
HIV and AIDS in comparison to the past few years, this
number remains staggering and ever increasing [1,4].
The advent of highly active antiretroviral therapy
(HAART) has brought with it a significant decrease in
AIDS-related deaths over the last ten years. Prior to the
development of raltegravir, HAART had been recom-
mended to consist of at least three different drugs target-
ing separate stages of the HIV life cycle: two nucleoside
reverse transcriptase inhibitors, plus either a non-nucleo-
side reverse transcriptase inhibitor such as efavirenz, or a
protease inhibitor [5,6]. Studies have shown that effective
administration of these HAART regimens can result in a
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large-scale decrease in plasma levels of viral RNA, as well
as a significant increase in CD4 cell count [7-9]. Further-
more, HAART has been shown to reduce the incidence of
opportunistic infections and HIV-associated cancers, con-
tributing to the significantly decreased number of HIV-
and AIDS-related deaths each year (and correspondingly
contributing to the much increased amount of people liv-
ing with the disease each year) [10]. However, HAART reg-
imens have been incapable of viral eradication, due in
part to the viral establishment of reservoirs within latently
infected and resting CD4+ T cells and CD8+ T cells [11-13].
Also, HAART has frequently led to the emergence of drug
resistant viral strains [14,15]. Hence, much innovation is
essential for the success of future anti-HIV drug research.
An area of much recent progress has been that of HIV-1 IN
inhibitor design. IN is an essential enzyme for viral repli-
cation, and it has no human homolog [for a recent review,
see Reference [16]]. IN catalyzes the insertion of reverse
transcribed viral cDNA into the host cell genome via a
multi-step process. The first step in integration occurs in
the host cell cytosol and is referred to as 3'-processing.
During this step, IN cleaves a dinucleotide from each viral
DNA terminus at a conserved CA sequence, yielding two
reactive 3' hydroxyl groups. Following this processing
step, IN associates with a number of viral and cellular pro-
teins, forming a pre-integration complex (PIC), and then
migrates to the nucleus. Within the nucleus the reactive
hydroxyl groups are utilized in nucleophilic attack upon
the host cell genome, a process known as strand transfer
[17]. IN multimerization is also required for formation of
the PIC. As a dimeric IN species is required for 3'-process-
ing, the strand transfer step calls for a tetrameric IN
arrangement. Proper integration of viral DNA into the
host cell genome leads to viral protein expression, matu-
ration, and propagation [18]. IN catalysis is vital to proper
HIV-1 replication and sustained infection, and potent
small-molecule IN inhibitors have been avidly sought
over the last ten years as a supplement to HAART and a
novel angle of attack against drug resistant viruses.
The birth of the diketo acids and the emergence 
of raltegravir
A previous large-scale, random screen of over 250,000
compounds yielded potent inhibitors, and the most active
compounds proved to be 4-aryl-2,4-diketobutanoic acids,
containing a distinct β-diketo acid (DKA) moiety that was
capable of coordinating metal ions within the IN active
site [19]. The active DKA containing compounds from this
study showed a significant preference for strand transfer
inhibition over that of 3'-processing in vitro. For example,
the most potent compound, L-731,988, exhibited a 70-
fold higher IC50 value of 6 μM for 3'-processing compared
to its 80 nM IC50 value for strand transfer inhibition.
Importantly, L-731,988 exerted a completely inhibitory
effect upon HIV-1 infection in a cell-based assay at a con-
centration of 10 μM. In a follow-up study [20], it was
found that the DKA and target DNA binding sites on IN
overlap and are both distinct from that of the viral DNA,
and also that the DKAs bind with a 1000-fold higher affin-
ity to IN in complex with 3'-processed viral DNA than to
non-complexed IN (10–20 μM versus 100 nM).
Simultaneously, a different group discovered and devel-
oped potent DKA compounds, leading to both the first
inhibitor co-crystallized with IN (5CITEP, Figure 1) and
the first clinically tested inhibitor (S-1360, Figure 1).
5CITEP was included in this group's 1999 patent [21],
which covered DKAs containing various indole and sub-
stituted indole groups. Specifically, 5CITEP possessed a
tetrazole group in place of the common DKA carboxylic
acid moiety. 5CITEP inhibited IN 3'-processing and strand
transfer at IC50 values of 35 μM and 0.65 μM, respectively
[22], and it was subsequently reported in complex with IN
in the vicinity of the active site residues Asp-64, Asp-116,
The structure of diketo acid-based HIV-1 integrase inhibitors Figure 1
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and Glu-152, providing the first crystal structure informa-
tion about IN [23]. Further modification led to the inclu-
sion of heterocyclic groups in place of the indoles,
culminating in the development of multiple nitrogen and
oxygen-containing heterocyclic analogs, all of which were
covered in a 2000 patent [24]. S-1360, or (Z)-1-[5-(4-
fluorobenzyl)furan-2-yl]-3-hydroxy-3-(1H-1,2,4-triazol-
3-yl)propenone, was the most promising of these com-
pounds and went on to become the first clinically tested
HIV-1 IN inhibitor. It exhibited a 20 nM IC50 for IN inhi-
bition in vitro, and it accomplished inhibition of HIV rep-
lication in MTT assays with EC50 and CC50 values of 200
nM and 12 μM, respectively [25,26]. Acceptable safety and
toxicology profiles were attained in animal models, and
Phase I trials showed good pharmacokinetics in a group of
24 healthy HIV-negative humans [25]. However, S-1360
failed efficacy studies due to its reduction in humans at
the carbon linked to the triazole heterocycle, yielding an
inactive metabolite that was rapidly cleared through glu-
curonidation in the non-cytochrome P450 pathway [27],
and its development was soon abandoned.
The DKA pharmacophore was subsequently transferred to
a naphthyridine carboxamide core, conferring similar
antiviral activity and strand transfer selectivity [28]. The
most active inhibitor from this class, L870,810 (Figure 1),
showed very promising activity, with IC50 values as low as
4 nM against multidrug-resistant viruses [29]. L870,810
soon became the second IN inhibitor to enter clinical tri-
als. However, liver and kidney toxicity surfaced after long-
term treatment in dogs, bringing a premature end to the
drug's clinical progress [30]. This relative success with
diketo acid structural analogs led to the derivation of a
class of N-alkyl hydroxypyrimidinone carboxylic acids,
which showed nanomolar activity against HIV-1 IN in
enzymatic assays and a good pharmacokinetic profile
(modest oral bioavailability, low plasma clearance, and
good half-life) in rats [31]. MK-0518, also known as ralte-
gravir (Figure 1), emerged as the most promising pyrimid-
inone carboxamide derivative and soon became the first
IN inhibitor to progress into Phase III clinical trials.
Though multiple resistant mutations have surfaced in
both treatment-experienced and treatment-naïve patients
[32], MK-0518 has exhibited low nanomolar and strand
transfer selective in vitro IN inhibition, an IC95 value of 31
nM in the presence of normal human serum (NHS), and
synergistic effects in combination with multiple current
antiretroviral drugs [15,33]. Raltegravir (a.k.a. Isentress™)
became the first FDA approved IN inhibitor in October of
2007 and is currently being administered as a new addi-
tion to HAART regimens.
Me-too drugs
Comparable to every innovation, promising new drugs
will be quickly followed into the market by multiple ana-
logs, most striking in their similarity to the original. With
an average cost of $2 billion to bring a single drug to mar-
ket [34] and only one in three drugs producing revenues
that match or exceed these average research and develop-
ment costs [35], one can imagine the temptation for phar-
maceutical companies to forego the pains of innovation
and rather simply modify current leads. There have been
differences of opinion regarding the value of these so-
called "me-too" drugs [36,37]. Some view that me-too
products are essential for drug optimization and progress,
and that they generate vital marketplace competition,
leading to better quality and lower costs. Still others argue
that slight structural modifications producing negligible
improvements in drug activity are a waste of time and
effort, and that the vast amount of money spent on com-
petitive advertisement could be invested instead into
actual innovation or the development of orphan drugs.
One of the clearest examples of me-too product genera-
tion can be seen in the statin drug market. There are cur-
rently six 3-hydroxymethylglutaryl coenzyme A reductase
inhibitors (statins) commercially available. However,
there has yet to be a large, randomized trial comparing the
clinical effects of equivalent doses of each statin upon pre-
vention of vascular disease. The six drugs differ slightly in
pharmacokinetics, and knowledge gained throughout
their design and development about the health implica-
tions of high cholesterol has been beneficial. However,
their structures, functions, and clinical effects are highly
homologous, and over 90% of physicians have been
shown to utilize at most three different statins for all of
their incident prescribing [38]. Another obvious instance
of me-too production has been the evolution of Astra-
Zeneca's Prilosec (omeprazole) to Nexium (esomepra-
zole). There are only two differences between the two
drugs – Prilosec contains a racemic mixture of the D- and
S-isomers of omeprazole while Nexium contains solely
the more potent S-isomer, and Nexium is protected by
patent and far more expensive than Prilosec. Furthermore,
Nexium has been shown in clinical trials to be only mar-
ginally more effective than Prilosec in control of stomach
acid levels [39]. Though there have been several examples
of me-too drugs providing a substantial increase in effica-
ciousness or decrease in toxicity – such as derivatives of
the anthracycline chemotherapeutic daunorubicin [40]
and the beta blocker propanolol [41] – very few FDA
approved me-too drugs actually exhibit a significant
enhancement of activity in comparison to their predeces-
sors. In fact, of the 1035 drugs approved by the FDA
between 1989 and 2000, only 361 contained new active
substituents, and less than half of these received a priority
FDA review due to the low likelihood of providing a sig-
nificant advantage over existing treatments [42].
An area in which me-too drug generation has been espe-
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design. Although raltegravir has become a modern block-
buster anti-HIV drug, multiple viral amino acid mutations
have already been identified that confer robust viral resist-
ance to the drug [43]. Specifically, mutations causing
invulnerability to raltegravir have been shown to contrib-
ute to an almost 25% virological failure rate within 48
months of treatment [44]. This viral drug resistance most
often results from the substitution of one of three amino
acids – Y143, Q148, or N155 – usually in combination
with at least one other mutation [44]. The specific substi-
tutions of G140S and E92Q are typically associated with
N155 and Q148 mutations, and the G140S/Q148H/R
double substitution has been shown to result in a >400-
fold viral resistance to raltegravir [45]. While the G140S
mutation displays only a weak resistance to raltegravir
(IC50 = 30 nM), the Q148H IN mutant is strongly resistant
(IC50 > 700 nM). Interestingly though, G140S has recently
been shown to effectively restore the poor replication abil-
ity of Q148H to near WT levels, illustrating its compensa-
tory nature [46]. Even with this resistance profile,
raltegravir has been the target of an excessive amount of
me-too research and development over the last two years.
Though, again, there have been historical instances of me-
too drugs significantly benefiting patients and instigating
medical progress, they have for the most part only bene-
fited pharmaceutical companies. Although it is definitely
possible that the next blockbuster anti-HIV drug could be
a raltegravir lookalike, we hypothesize that raltegravir me-
too drugs, targeting a virus that exhibits an extraordinary
rate of resistance evolution, will experience a low proba-
bility of success in the clinical setting due to viral resist-
ance and cross-resistance issues.
Me-too or second generation?
In contrast to me-too drugs, second generation HIV-1 IN
inhibitors benefit patients. In order to be considered a
bona fide second generation inhibitor, a compound of
interest must meet at least one of three criteria (Figure 2).
First, a second generation inhibitor may exhibit a new
mode of action and/or contain novel active substitu-
ent(s). A second generation inhibitor may also possess
significantly improved potency and/or significantly
decreased toxicity. Thirdly, a second generation inhibitor
may exhibit potency while avoiding cross-resistance from
mutants resistant to similar drugs. Obviously, the more
criteria a selected drug meets, the more success it will
enjoy in the clinical setting and in the global market. A
recent example of a second generation drug that has nar-
rowly avoided me-too labeling is the protease inhibitor,
darunavir. Darunavir is the 10th protease inhibitor to be
marketed in the United States, and it was approved by the
FDA on June 23, 2006. Darunavir's chemical structure is
almost identical to its precursor, amprenavir, in that it
simply contains a double-ringed terminal bis-tetrahydro-
furan group in place of the single-ringed terminal tetrahy-
drofuran on amprenavir. Additionally, darunavir and
amprenavir occupy a highly overlapping volume in the
protease active site. However, darunavir's two additional
oxygen atoms upon its bis-tetrahydrofuran moiety con-
tribute to a two order of magnitude increase in binding
affinity in comparison to amprenavir, by forming strong
hydrogen bonds with the main chain atoms of amino
acids Asp-29 and Asp-30 [47]. This tighter binding leads
to an increased ability of darunavir to fit within the pro-
tease envelope and to exhibit potent activity against even
multi-drug resistant viral strains. Darunavir specifically
retains nanomolar IC50 values in the presence of muta-
tions resistant to ritonavir, nelfinavir, indinavir, saquina-
vir, and even amprenavir (mutations at L10F, V32I, M46I,
I54M, A71V, and I84V) [48]. So, although darunavir's
structural and mechanistic properties are me-too-like, its
resistance profile created by its relatively high binding
affinity is much different than all preexisting protease
inhibitors. It is therefore considered a second generation
drug. The structural and mechanistic properties of recent
raltegravir me-too compounds are highly analogous, as
are the pharmacokinetics. We predict that the resistance
profiles will be nearly identical as well, precluding much
clinical success.
Raltegravir me-too analogs
Most of the recent raltegravir me-too drugs comply with
the general diketo acid pharmacophore structural require-
ments – or a hydrophobic aromatic (usually fluoroben-
zyl) component and a variable acidic component linked
to either side of a DKA linker (Figure 1). This linker usu-
ally consists of a γ-ketone, an enolizable α-ketone, and a
carboxylic acid, but the carboxylic acid has been substi-
tuted with other acidic (tetrazole and triazole) and basic
(pyridine) bioisosters [49]. Whereas the aromatic DKA
Requirements for "second generation drug" classification Figure 2
Requirements for "second generation drug" classifi-
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pharmacophore substituent confers strand transfer selec-
tivity, the acidic component contributes to 3'-processing
inhibitory potency [50,22].
Clinically tested me-too IN drugs
MK-2048
Research into second generation DKA inhibitors shortly
after the FDA approval of MK-0518 led to the design of a
set of tricyclic hydroxypyrroles that mimicked the com-
mon DKA metal binding pharmacophore. Optimization
of a derived set of 10-hydroxy-7,8-dihydropyrazinopyrrol-
opyrazine-1,9-dione compounds resulted in one of the
first raltegravir me-too leads, MK-2048 (Figure 1). MK-
2048 has exhibited an IC95 of 40 nM in the presence of
50% NHS, favorable pharmacokinetics, and potent
antiretroviral activity against four IN mutants displaying
raltegravir resistance [51,52].
GS-9137 (elvitegravir)
Early modification of the DKA motif by Japan Tobacco
resulted in the design of a group of 4-quinolone-3-glyox-
ylic acids [49] that retained the coplanarity of DKA func-
tional groups. A potent compound from this original
study contained only a β-ketone functional group and a
carboxylic acid functional group, which were coplanar,
and showed a 1.6 μM IC50 value in a strand transfer assay.
Derivatives of this parent compound exhibited up to a 7.2
nM IC50 value in strand transfer assays and a 0.9 nM EC50
in an antiviral assay. This activity proved that a monoketo
motif could be an efficacious alternative to the accepted
DKA. A 2005 license agreement between Japan Tobacco
and Gilead Sciences led to the clinical development of GS-
9137 (a.k.a. elvitegravir) [Figure 1, [43]], a quinolone car-
boxylic acid strand-transfer specific inhibitor that dis-
played an IC50 of 7 nM against IN and an antiviral EC90 of
1.7 nM in the presence of NHS. In terms of pharmacoki-
netics (Additional file 1), in rat and dog elvitegravir dis-
played a 34% and 30% bioavailability, a 2.3 h and 5.2 h
half-life, and a 8.3 mL/min/kg and 17 mL/min/kg clear-
ance, respectively. Interestingly though, its half-life in
human was shown to increase from 3 hours when dosed
alone to 9 hours when boosted with the protease inhibi-
tor, ritonavir [53]. Similarly, its bioavailability increased
20-fold when administered in combination with ritona-
vir. These observations back a valid argument that elvite-
gravir may become a second-generation IN inhibitor, in
that its significantly improved pharmacokinetic profile
when boosted may increase patient compliance by allow-
ing a simple once daily treatment (raltegravir is adminis-
tered twice daily). Similar to raltegravir, though,
elvitegravir has been shown to provoke T66I and E92Q
viral resistance mutations, as well as substitutions of
amino acids flanking raltegravir-induced substitution
sites (Q146P and S147G) [54].
GSK-364735
In studies to develop follow-on analogs of S-1360, the two
involved groups jointly discovered a novel lead naphthy-
ridinone, GSK-364745 (Figure 1). This compound con-
tains a hydrophobic fluorobenzyl substituent flexibly
linked to a chelatable quinolone region. GSK-364735
inhibited IN in an in vitro strand transfer assay with an
IC50 of 8 nM, and it showed an antiviral EC90 value of 40
nM in MT-4 cells in the presence of 20% NHS. Acceptable
pharmacokinetics were achieved, with bioavailabilities of
42%, 12%, and 32%; half-lives of 1.5 h, 1.6 h, and 3.9 h;
and clearances of 3.2 mL/min/kg, 8.6 mL/min/kg, and 2
mL/min/kg in rat, dog, and rhesus monkey, respectively
(Additional file 1). However, when tested against mutant
viruses, the compound exhibited greatly decreased activity
– 17-fold reduction against T66K, 210-fold reduction
against Q148K, 73-fold reduction against Q148R, and 23-
fold reduction against N155S [55].
BMS-707035
A pyrimidine carboxamide similar in structure to raltegra-
vir was recently propelled into Phase II clinical trials by a
separate group. This compound was different from ralte-
gravir in that raltegravir's 1,3,4-oxadiazole group was sub-
stituted with a cyclic sulfonamide moiety (Figure 1), but
its in vitro potency was similar with an IC50 value of 20
nM. However, multiple mutations were almost immedi-
ately observed to have occurred in viral response to treat-
ment with BMS-707035, which included V75I, Q148R,
V151I, and G163R [32]. Unfortunately, the severity of
resistance conferred by each of these mutations has not
been disclosed, nor have pharmacokinetic properties of
the drug. What is known, however, is that the drug did not
last long in Phase II trials, and testing was abruptly termi-
nated in early 2008 [56]. An explanation of the termina-
tion of the trial has not been publicly provided.
Novel me-too classes
Dihydroxypyrimidine-4-carboxamides
Soon after promising clinical data regarding the progress
of MK-0518 became available, a novel DKA-related class
of IN inhibitory compounds (Figure 3, Additional file 1)
was developed through screening of inhibitors of HCV
polymerase, which demonstrates a high degree of struc-
tural similarity to IN [31]. Specifically, IN and HCV
polymerase possess a similar active site amino acid geom-
etry, and both utilize two magnesium ions in their cataly-
sis. A class of dihydroxypyrimidine carboxamides was
derived as HCV polymerase inhibitors from DKAs, and
they were found to exhibit improved drug-like properties
and correct Mg2+ binding geometry. Most of these com-
pounds were inactive against IN, but a substitution of the
free carboxylic acid with a benzyl amide yielded com-
pound 1, with nanomolar IN inhibitory activity in enzy-
matic assays. Compound 1  showed a decentRetrovirology 2009, 6:25 http://www.retrovirology.com/content/6/1/25
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pharmacokinetic profile, with a bioavailability of 15%,
plasma clearance of 5 mL/min/kg, and a half-life of 3
hours. Further structure activity relationship (SAR) studies
upon the amide moiety of 1 led to the identification of a
superior  para-fluorobenzyl substituent (compound 2).
Compound 2 exhibited an IC50 of 10 nM in the enzymatic
assay, as well as an improved oral bioavailability in rats of
29%. However, both compounds 1 and 2 were inactive in
cell-based assays, due to poor solubility, poor cell perme-
ability, and significant plasma protein binding [31].
This group pushed on in their search for raltegravir me-
too drugs with further SAR studies upon the above N-alkyl
hydroxypyrimidinone lead compounds (Figure 3). As a
benzyl amide substitution of a free carboxyl instilled
nanomolar activity upon said compounds, a library of
over 200 different amide modifications was synthesized
and screened for inhibitory potency [57]. A 4-fluoro-sub-
stituted benzene was shown to be optimal for IN inhibi-
tion, with an IC50 value in enzymatic assays of 10 nM.
However, though compounds optimized in this fashion
were active in the enzymatic assay, they lacked potency in
cell based assays. The thiophene ring in the 2-position of
the pyrimidine core was shown to have little effect upon
the interaction of the compound with IN, and so this posi-
tion was chosen for more dramatic changes influencing
physiochemical properties of inhibitors. Introduction of a
basic group to a 2-benzyl derivative resulted in increased
cell permeability and inhibition of viral replication in the
presence of fetal bovine serum (FBS) with a CIC95 of 300
nM (compound 3). This compound showed an oral bioa-
vailability of 59% and 93%, a half-life of 1.73 h and 6.78
h, and a plasma clearance of 14 mL/min/kg and 0.5 mL/
min/kg in rats and dogs, respectively. However, weak
activity in the presence of 50% NHS exposed the mobile
nature of chosen 2-position substituents. In response the
phenyl group at this position was removed and the NH
methylated, to confer reduced lipophilicity (and reduced
plasma protein binding) but maintain the presence of the
mandatory amino group. Compound 4 was thus born,
exhibiting a 95% human plasma protein binding and a
400 nM CIC95 in the presence of 50% NHS. Pharmacoki-
netics of compound 4 included an oral bioavailability of
27% and 90%, a half-life of 0.43 h and 6.0 h, and a
plasma clearance of 75 mL/min/kg and 2 mL/min/kg in
rats and dogs, respectively. Separately, smaller acyclic
amines were substituted into the 2 position and similarly
assayed for activity [57]. It was found that a dimethylami-
nomethyl substituent separated by an sp3-carbon spacer
bestowed significant cell based potency, at a CIC95 of 78
nM in 50% NHS (compound 5). In rats, dogs, and mon-
keys, compound 5 had a prolonged plasma half-life (2.1,
4.8, and 1.9 h, respectively), moderate to low clearance
(16, 1.9, and 15 mL/min/kg, respectively) and moderate
to excellent oral bioavailability (28%, 100%, and 61%,
respectively) [57].
N-methylpyrimidones
To improve cell-based potency and bioavailability of the
above molecules, this group began to study the effect of
methylation of their N-1 pyrimidine nitrogens (Figure 4,
Additional file 1). The rationale for this decision was
based upon their discovery that the amine contained in
the ring must occupy the benzylic position with respect to
the pyrimidine and that small alkyl groups are preferred
on the nitrogen of the saturated heterocycle [57]. A
methyl group was initially scanned on the pyrrolidine
ring, and substitution on position 4 gave the best enzy-
matic activity. Substitution of the free hydroxyl group of a
resulting trans-4-hydroxy pyrrolidine with a methoxy sub-
stituent produced potent activity (compound 6) in both
in vitro (IC50 = 180 nM) and cell-based assays (CIC95 = 170
nM in 50% NHS) [58]. From here the group tested other
The evolution of dihydroxypyrimidine-4-carboxamides Figure 3
The evolution of dihydroxypyrimidine-4-carboxam-
ides.
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substitutions, of which a fluorine (compound 7 – CIC95 =
250 nM) or a difluoro derivative (compound 8 – CIC95 =
170 nM) were well accepted. Activity was found to be fur-
ther augmented by substituting a six-membered derivative
in position 2 of the pyrimidine, and the morpholine
derivative 9 and piperidine derivative 10 displayed
slightly improved cell-based potencies (100 nM and 190
nM CIC95 in 50% NHS, respectively). In terms of pharma-
cokinetics, the morpholine derivative 9 was the most ideal
candidate for further testing, with bioavailabilities of
92%, 100%, and 53%; half-lives of 1.5 h, 10 h, and 1.4 h;
and plasma clearance rates of 22 mL/min/kg, 3 mL/min/
kg, and 14 mL/min/kg in rat, dog, and rhesus monkey,
respectively [58].
A further optimization study analyzed the enzymatic and
pharmacokinetic implications of a different, tbutyl substi-
tution at the C-2 position of the pyrimidine scaffold of the
above compounds [Figure 4, [59]]. Further introduction
of a benzylamide to the right side of the scaffold proved
necessary for activity in serum conditions. Multiple deriv-
atives were designed using the N-methyl pyrimidone scaf-
fold, including a sulfone (compound 11) and an N-
methyl amide (compound 12) that showed CIC95s of 20
nM and 10 nM in 50% NHS, respectively. This encourag-
ing data inspired further substitutions of the 2-N-methyl
carboxamide, for optimization of pharmacokinetic
behavior. An unsubstituted amide 13 exhibited a promis-
ing inhibitory profile (IC50 = 20 nM in enzymatic assay,
CIC95 = 10 nM in 50% NHS), prompting multiple further
substitutions of the N-methyl residue with an N-ethyl
(compound 14) and an iN-propyl (compound 15). The
pharmacokinetic profiles of 11, 12, and 13 were not opti-
mal (Additional file 1), and none of these substitutions
were beneficial in this respect. Bioavailability was 17%,
18%, and 23%; half-life was 1.8 h, 1.6 h, and 3.6 h; and
plasma clearance was 37 mL/min/kg, 24 mL/min/kg, and
55 mL/min/kg in rat for 11, 12, and 13, respectively [59].
Dihydroxypyrido-pyrazine-1,6-diones
Parallel to the above N-methylpyrimidone studies, the
same group was working toward optimization and cyclic
constraint of the dihydroxypyrimidine-4-carboxamide
amide side chain, yielding a novel class of dihydroxypyri-
dopyrazine-1,6-dione compounds [Figure 5, [60]].
Coplanarity of the amide carbonyl group in the con-
strained ring with respect to the dihydroxypyridinone core
and a resulting limitation of flexibility of the 4-fluoroben-
zyl side chain (compound 16) were shown through
molecular modeling to be essential for inhibitory activity.
Compound 16 inhibited IN strand transfer in vitro at an
IC50 of 100 nM and HIV replication in cell culture at a
CIC95 of 310 nM, with little cytotoxicity. Limited pharma-
cokinetic data has been provided for this class of com-
pounds, but compound 16 was shown to have a 69% oral
bioavailability in rats, and plasma concentrations were
maintained between 0.64 and 0.50 μM from the second to
the twenty-fourth hour (Additional file 1). There was con-
cern about the dihydroxypyrimidone core and its metab-
olites irreversibly associating with liver microsomal
proteins, but only a non-significant level (<50 pmol
equiv/mg/60 min) of interaction was observed [60].
Bicyclic pyrimidones
Recently, the aforementioned importance of a β-amino
substituent in the 2-position of the pyrimidine scaffold
and the beneficial effect of the 1N-methylation were
exploited in a systematic constraint of the 1N-methyl on
the 1N-methylpyrimidinone scaffold (Figure 6, Addi-
tional file 1). With unsubstituted benzylmethylamine
derivatives showing nanomolar enzymatic inhibition pro-
Dihydroxypyrido-pyrazine-1,6-dione representative example Figure 5
Dihydroxypyrido-pyrazine-1,6-dione representative 
example.
N
N
O OH
OH
O
F
16
The evolution of bicyclic pyrimidones Figure 6
The evolution of bicyclic pyrimidones.
17 18
N
N
O
OH
H
N
O
F
N
O
S
N
O O
19
20 21
22
N
N
O
OH
H
N
O
F
N
S
OO
N
N
O
OH
H
N
O
F
N
S
N
OO
N
N
N
O
OH
H
N
O
F
N
S
N
OO
N
N
O
OH
H
N
O
F
N
O
N
O
N
N
O
OH
H
N
O
F
N
O
N
ORetrovirology 2009, 6:25 http://www.retrovirology.com/content/6/1/25
Page 8 of 14
(page number not for citation purposes)
files similar to those of derivatives with saturated ring side
chains (though little inhibition of viral replication in cell
culture), it was decided that the 2- -nitrogen would be
modified to optimize physiochemical properties of
pyrimidone compounds [61]. For example, introduction
of a sulfonamide (compound 17) resulted in a low shift in
activity in serum conditions, suggesting an increased level
of cell permeability. The (R)-17 enantiomer displayed a 7
nM enzymatic IC50 value, a 31 nM CIC95 in 50% NHS
(two-fold more potent than its (S)-17 enantiomer con-
temporary), and acceptable pharmacokinetics including a
17% bioavailability and 55 mL/min/kg plasma clearance
in rat. Sulfonamide derivatives showed similarly decent
profiles (compound 18 = 12 nM IC50 against strand trans-
fer, 86 nM CIC95 in cells in 50% NHS, and a 47% bioavail-
ability and 48 mL/min/kg plasma clearance in rats).
However, an even more significant improvement in
potency occurred upon changing the sulfonamide moiety
to a tetrasubstituted sulfamide (compound 19). The (R)-
19 enantiomer inhibited IN with an IC50 value and a
CIC95 value of 7 nM and 44 nM, respectively, but pharma-
cokinetics (9% bioavailability in rhesus monkey) were
inadequate. Introduction of a more polar N-methylpiper-
azine (compound 20), however, produced a compound
whose (S)-20 enantiomer inhibited IN at a CIC95 of 6 nM
in cell culture in the presence of 50% NHS. This com-
pound was much more stable toward glucuronidation
than its sulfamide counterpart, but low bioavailability
and high plasma clearance in rats and dogs neutralized its
promise. It was hence necessary to make use of other
nitrogen functionalizations in order to optimize these
pharmacological properties. The substitution of ketoam-
ides and enlarged rings (compounds 21 and 22, respec-
tively) resulted in potent inhibition of IN in cell based
assays and much improved pharmacokinetics. The (S)-
enantiomers of both compounds achieved CIC95s of 43
nM and 13 nM in cell culture, respectively, as well as mod-
erate pharmacologic properties in rats, dogs, and (com-
pound (S)-22 only) monkeys [61].
Pyrrolloquinolones
A different group has recently built upon their prior opti-
mization of the clinically efficacious L870,810 [62,63] by
varying C5 substituents within their compounds' tricyclic
scaffolds (Figure 7, Additional file 1). They originally
developed the tricyclic scaffold to provide a pre-organ-
ized, energetic improvement to L870,810's unfavorable
energy consumption upon rotational conversion from
free state to bound state, leading to a more soluble and
potent compound 23  [62]. In their recent work, C5-
amino derivatives were prepared and assayed for improve-
ment in strand transfer inhibitory potency and pharma-
cokinetics, due to their projected higher stability against
hydrolysis than analogous carbamates or sulfamates [64].
The most promising leads turned out to be a C5 sulfona-
mide (compound 24), a C5 sulfonylurea (compound 25),
and a C5 sultam (compound 26). Compounds 24 and 25
retained potency in the presence of serum albumin and α-
1 acidic glycoproteins, while 26 was negatively affected.
Though the sultam 26 showed a lower IC50 than the sul-
fonamide 24 and sulfonylurea 25 in enzymatic assays (13
nM as opposed to 28 nM and 62 nM, respectively), it
lacked potency in cell culture in 50% NHS (EC50 49 nM as
opposed to 11.4 nM and 8.4 nM, respectively). It is impor-
tant to note that raltegravir showed an EC50 value of 16
nM in cell culture in the presence of 50% NHS. Com-
pound 26 was additionally lacking in bioavailability in
both rat (4%) and dog (8%). However, compounds 24
and 25 showed slightly more promising profiles, with bio-
availabilities of 15%/13% and 45%/16% and half-lives of
1.1 h/0.9 h and 4.9 h/4.5 h in rat and dog, respectively
[64]. This study exemplified the importance of rigidifying
inhibitor pharmacophores in terms of conferring favora-
ble potency and pharmacokinetic properties.
Validation of resistance profiles of me-too raltegravir 
analogues
Though there is minor variation in the in vitro activity of
the above me-too IN inhibitors, their structures, mecha-
nisms of action, and pharmacokinetics are highly similar.
We believe that the development of me-too compounds
may yield a relatively low amount of clinical success due
to their similarities, and also due to the fact that nearly
identical resistance profiles will be evoked by their appli-
cation. However, we would like to note that it is definitely
possible for a raltegravir me-too analog to evolve into a
second-generation IN inhibitor. To further elucidate our
viewpoint, we utilized the molecular docking program
GOLD version 3.2 to conduct a docking study, using both
the X-ray determined structure of 1BL3 IN complexed
with an Mg2+ ion, and a collection of significant, above-
described me-too compounds (Figure 8); for a detailed
The evolution of pyrrolloquinolones Figure 7
The evolution of pyrrolloquinolones.
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procedure, see [65]. We propose that residues essential to
the compounds' interaction with IN will obviously be
prime candidates for resistance mutation. Furthermore,
we hypothesize that the test of time will show that all of
these me-too inhibitors will probably exhibit highly sim-
ilar resistance profiles. As raltegravir has undergone exten-
sive resistance profiling since the inception of its clinical
employment (Table 1), we first compared our predicted
interaction residues (Figure 8) to these experimental pro-
files, as a validation of the reliability of our technique. We
found that five of our predicted interaction residues (T66,
E92, Y143, Q148, and N155) have been already observed
to confer a range of anywhere from 5- to 35-fold resist-
ances to raltegravir inhibition of viral replication, respec-
tively [66-69]. We also saw that raltegravir makes direct
interactions with the three residues encompassing the IN
catalytic DDE motif (D64, D116, and E152), including a
hydrogen bond with the glutamate. With this technique
corroboration in hand, we decided to similarly predict the
interaction residues of raltegravir's progenitors and a few
me-too analogues, in order to provide evidence for our
assertion that these compounds will ultimately experience
a low probability of success in viral eradication, due to
their generation of identical resistance profiles. As S-1360
was the first clinical IN inhibitor candidate, we thought it
would be interesting to evaluate the similarity between its
predicted interaction profile with 1BL3 (Figure 8) and that
of raltegravir. We found that an identical interaction
occurs between the two drugs and IN (D64, T66, D116,
Y143, Q148, E152, and N155), but predicted an addi-
tional interaction of raltegravir with E92. This observation
has been verified in clinical experimental resistance profil-
ing, as mutation of E92 has not been observed for S-1360,
but the E92Q mutation has conferred up to a 7-fold viral
resistance to raltegravir [25,26,70]. We next observed the
interaction profile of 1BL3 with L870,810 (Figure 8), as
this is the naphthyridine carboxamide compound that
directly led to the development of pyrimidinone carboxa-
mides. We found that L870,810 and raltegravir similarly
interacted with D64, T66, D116, Q148, E152, and N155.
However, we saw here that only raltegravir interacted with
E92. Though this residue has been observed to be mutated
to a glutamine in response to L870,810 treatment, the
mutation has conferred at most only a 2-fold resistance to
the drug, while the same mutation confers up to a 7-fold
resistance to raltegravir (Table 1) [29,71]. The fact that we
did not observe a significant interaction between
L870,810 and E92 in our docking study further confirms
the relatively decreased importance of this residue in viral
resistance to the compound. Along the same lines, we did
see an interaction of L870,810 with V151, an interaction
that was not present in our docking of raltegravir. In clin-
ical experimental resistance profiling, the V151I mutation
has been observed to confer up to an 18-fold resistance to
L870,810, while the same mutation had a negligible effect
on viral resistance to raltegravir (Table 1) [29,71]. The
highly homologous naphthyridine carboxamide candi-
date, L870,812, has shown an interaction profile virtually
identical to that of L870,810 in our docking study, and
experimental resistances obtained in clinical observation
have been identical as well [29,71]. As elvitegravir (GS-
9137) and GSK-364735 have already been shown to
exhibit near identical resistance profiles to raltegravir
(Table 1) [67,71-73], we next used our docking technique
to attempt to effectively predict these interactions (Figure
8). For GSK-364735, we were able to predict the interac-
tion with IN residues Y143 and Q148, as well as the three
members of the DDE motif. We then predicted that, sim-
ilar to raltegravir, elvitegravir interacts with T66, E92,
Y143, Q148, and the D116 and E152 of the DDE motif.
We also saw that elvitegravir interacts with G140, and the
G140S mutation has been shown to be associated with a
Docking poses of selected HIV-1 integrase inhibitors upon  the 1BL3 IN crystal structure Figure 8
Docking poses of selected HIV-1 integrase inhibitors 
upon the 1BL3 IN crystal structure. A, MK-0518; B, S-
1360; C, L870,810; D, GSK-364735; E, GS-9137; F, com-
pound 2; G, compound 11; H, compound 16; I, compound 
17; J, compound 26.
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Table 1: Effect of single mutations on IN sensitivity to clinically tested inhibitors.
Mutation S-1360 L870, 810 MK-0518 GS-9137 GSK-364735
T66I ++ + ++ +++ +
L68V ++
L68I ++
V72I + ++
L74M ++++ + + ++
E92Q ++ + ++ +++ ++
Q95K ++ ++
F121Y +++ ++ ++ +++ +++
T124A + +
T125K + + +
E138K + + + +
G140S ++ + ++
P145S ++ +
Q146R ++ + +++ +
S147G ++ + ++
Q148H +++ +++ ++
Q148R ++++ +++ +++++ ++++
Q148K ++++ +++ ++++ +++++
V15II +++ + ++
S153Y ++ + ++ +
N155H ++ +++ +++
N155S +++ ++ ++ +++
E157Q ++
R263K ++
E92Q/N155H ++++ ++++
F121Y/T125K ++ ++++
G140S/Q148H +++++ +++++
V72I/F121Y/T125K/V151I +++++ +++++
Fold change in potency compared to wild type: + <2, ++ 2–10, +++ 11–50, ++++ 51–100, +++++ >100Retrovirology 2009, 6:25 http://www.retrovirology.com/content/6/1/25
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4-fold viral resistance to the drug, while the same muta-
tion confers only a 1.6-fold resistance to raltegravir (Table
1). Again, the fact that we did not observe a significant
interaction between raltegravir and G140 in our docking
study further confirms the relatively decreased importance
of this residue in viral resistance to raltegravir, but rather
its nature of compensation for more meaningful muta-
tions, such as Q148H.
Prediction of future me-too resistance profile 
similarities
With the above data significantly validating the reliability
of our docking technique, we moved forward with the
prediction of resistance profiles of selected me-too ralte-
gravir analogues (Figure 8). Here, we will describe the
interactions of one of the most potent (in terms of in vitro
IC50 inhibition of IN) compounds from each of the above-
described classes of me-too inhibitors with the 1BL3 IN
crystal structure. The dihydroxypyrimidine-4-carboxam-
ide compound 2 exhibited an IC50 value of 10 nM against
IN [31]. However, our predicted interaction profile for
this compound shows that it will most likely be ineffective
against raltegravir-resistant viruses. We show that com-
pound 2 interacts with 1BL3 IN residues D64, T66, E92,
D116, Q148, E152, S153, and N155 – virtually the exact
binding pocket as raltegravir. The N-methylpyrimidone
compound 11 exhibited an IC50 value of 20 nM against IN
[58]. Our predicted interaction profile for this compound
encompasses the 1BL3 residues D64, T66, E92, D116,
G140, Y143, Q148, E152, and N155 – virtually the exact
binding pocket as raltegravir. The dihydroxypyrimido-
pyrazine-1,6-dione compound 16 had a moderate IC50
value of 100 nM against IN [60]. Our predictive docking
procedure calculated an interaction profile including IN
residues D64, E92, D116, and Q148. E92Q and Q148R
mutations have already been observed to confer 7-fold
and 35-fold resistances to raltegravir, respectively. The
bicyclic pyrimidone compound 17 has displayed a potent
IC50 value of 7 nM against IN in vitro [61]. However, our
predicted interaction profile implicates the 1BL3 residues
D64, T66, E92, D116, Y143, Q148, and E152 as contact
points. This is virtually the same binding pocket as that of
raltegravir. Finally, the pyrrolloquinolone compound 26
has exhibited an IC50 value of 13 nM against IN [64].
Again however, we show that this compound will interact
with IN in a considerably similar manner to that of ralte-
gravir, contacting residues D64, E92, D116, G140, and
E152. If our predictions prove to be correct, these candi-
date drugs will probably fail to replace raltegravir. Though
me-too evolution into a new blockbuster drug is always a
possibility, the above IN me-too drugs appear to have a
small chance of improving the clinical outlook of HIV
patients with raltegravir-resistant viral strains.
Conclusion
As me-too drugs have been historically shown to be min-
imally progressive in terms of improvement of disease
prognosis, their lack of utility is exemplified in the case of
HIV. A plethora of polymorphic resistance mutations
have almost instantly arisen in response to both raltegra-
vir and the purported second-generation IN inhibitor,
elvitegravir [74]. It is clear to see that the virus is capable
of eventually avoiding interaction with many a once
potent inhibitor, and attempts at recreating these original
interactions will most likely fall victim to the same mode
of viral escape. Although some pharmacokinetic proper-
ties may be optimized through me-too drug development
research, and some profitable drugs may be cleared for
marketing, the long term efficacy of most of these drugs
will likely be susceptible to the ever present mutational
ultra-competence of HIV. As stated earlier, there is a thin
line between drug development and me-too spawning.
Simple pharmacokinetic improvement can drastically
augment the daily lives of patients and the quarterly prof-
its of companies, but the simple fact remains that HIV will
most likely not be eliminated by a 2% increase in oral bio-
availability. Dramatically diverse classes of molecules
look to be required for inhibition of viral enzymes in a
long term fashion. Thus, in our eyes, the only hope for
complete viral eradication is innovation.
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